Prevention of the hemorrhagic hypotension-induced hepatic arterial vasoconstriction by L-arginine and naloxone.
The possible involvement of the L-arginine-nitric oxide pathway and endogenous opioid mechanisms in the hemorrhagic hypotension- (HH) induced changes of hepatic arterial blood flow and vascular resistance was studied in cats. During HH hepatic arterial blood flow was significantly higher both in L-arginine- and naloxone-treated animals than in controls. Furthermore, HH induced a significant increase of the hepatic vascular resistance in the control group, which was prevented by L-arginine or naloxone treatment. Because inhibition of the nitric oxide synthesis by N(G)-nitro-L-arginine in normotensive cats induced a similar increase of the hepatic vascular resistance to that observed during HH in the control group, our results indicate that impairment of the endothelial function may be responsible for the hemorrhage-induced L-arginine- and naloxone-reversible hepatic arterial vasoconstriction. This hypothesis is consistent with our previous observations demonstrating the development of endothelial dysfunction in the feline hepatic artery during HH.
Benyó
Z
Z
Experimental Research Department, 2nd Institute of Physiology, Semmelweis University of Medicine, Budapest, Hungary.
Szabó
C
C
Kovách
A G
AG
Sándor
P
P
D000818:Animals; D001120:Arginine / Q000627:therapeutic use*; D002415:Cats; D004353:Drug Evaluation, Preclinical; D006470:Hemorrhage / Q000150:complications / Q000188:drug therapy*; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D008099:Liver / Q000098:blood supply*; D008297:Male; D009270:Naloxone / Q000627:therapeutic use*; D019335:Nitroarginine / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects*
D019335:Nitroarginine; D009270:Naloxone; D001120:Arginine